Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 25, 2016. The document serves as a transaction notification regarding a Person Closely Associated (PCA) with a Principal Director, Manager, or Representative (PDMR), rather than a periodic financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to a specific securities transaction notification.
- Instrument: GlaxoSmithKline plc American Depositary Shares (ADSs)
- Transaction Price: $40.68 per ADS
- Transaction Volume: 1 ADS
- Transaction Date: October 24, 2016
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single increase of 1 ADS held by Dr. K. Slaoui (PCA of Dr. M. M. Slaoui, Chairman, Global Vaccines). This increase resulted from the revaluation of the cash element of a notional investment within the GSK 401(K) plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of a specific insider transaction.
Investor Verification Checklist
- Verify the identity of Dr. K. Slaoui and their relationship to Dr. M. M. Slaoui.
- Confirm the market price of GSK ADSs on October 24, 2016, to validate the reported transaction price of $40.68.
- Review the GSK 401(K) plan rules regarding notional allocations and cash element revaluations.
- Note that this filing does not contain financial performance data; refer to the most recent Form 20-F or quarterly reports for financial metrics.